Pilot study to support medication adherence following ACS
Research type
Research Study
Full title
A Pharmacist-Led Hospital-Based Intervention to Support Medication Adherence Following Acute Coronary Syndrome: An Intervention Cohort Study
IRAS ID
232133
Contact name
John Weinman
Contact email
Sponsor organisation
King's College London
Clinicaltrials.gov Identifier
Duration of Study in the UK
0 years, 10 months, 31 days
Research summary
Background
Medication adherence following acute coronary syndrome (ACS) is often sub-optimal and is associated with poor clinical outcomes. There is evidence that psychosocial factors such as treatment beliefs play a role in determining adherence (Crawshaw et al., 2016) and have the potential to be changed through intervention (Johnston et al., 2016).Aims
The aim of this proposed study is to pilot a pharmacist-led hospital-based intervention to support medication adherence in patients following ACS. This proposed study follows on from a recent feasibility study (IRAS: 212827).Methods
A non-randomised intervention cohort study (i.e. controlled before-and-after (CBA) study) will be conducted. Patients diagnosed with ACS will be recruited from a single NHS inpatient site over two recruitment periods. Informed consent will be taken. Pharmacists will be trained by the research team to deliver the intervention between recruitment periods, thus creating two comparable groups (control/'before' group vs. intervention/'after' group).The intervention will challenge both perceptual (Session 1) and practical barriers (Session 2) to good medication-taking behaviour during two face-to-face sessions between patient and pharmacist. Patients will complete a questionnaire before Session 1 and a worksheet during Session 2.
Session 1 will focus on treatment beliefs and challenge any misconceptions patients have about the medications they have been prescribed. Session 2 will involve patients formulating action plans with the pharmacist to help establish a clear medication-taking routine for when they return home. Patients will be followed up at two time-points - 6 weeks and 12 weeks post-discharge. Data will be collected via self-report.
Outcomes
The primary outcome of this proposed study are treatment beliefs, measured using the Beliefs about Medicines Questionnaire-Specific (BMQ-S) (Horne, Weinman & Hankin, 1999). Our secondary outcome will be self-reported medication adherence measured using the Medication Adherence Report Scale (MARS-5) (Horne & Weinman, 2002). Depression, self-efficacy and satisfaction with medicines information provision will also be measured.REC name
London - Chelsea Research Ethics Committee
REC reference
17/LO/1706
Date of REC Opinion
8 Nov 2017
REC opinion
Further Information Favourable Opinion